Vaxxinity (Vaxxinity) Additional Paid-In Capital : $374.76 Mil(As of Dec. 2023)

View and export this data going back to 2021. Start your Free Trial

What is Vaxxinity Additional Paid-In Capital?

Vaxxinity's quarterly additional paid-in capital increased from Jun. 2023 ($371.85 Mil) to Sep. 2023 ($373.68 Mil) and increased from Sep. 2023 ($373.68 Mil) to Dec. 2023 ($374.76 Mil).

Vaxxinity's annual additional paid-in capital increased from Dec. 2021 ($357.82 Mil) to Dec. 2022 ($366.80 Mil) and increased from Dec. 2022 ($366.80 Mil) to Dec. 2023 ($374.76 Mil).

Vaxxinity Additional Paid-In Capital Historical Data

The historical data trend for Vaxxinity's Additional Paid-In Capital can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Vaxxinity Additional Paid-In Capital Chart

Vaxxinity Annual Data

Trend

Dec19

Dec20

Dec21

Dec22

Dec23

Additional Paid-In Capital

3.59

4.68

357.82

366.80

374.76

Vaxxinity Quarterly Data
	Dec19	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23
Additional Paid-In Capital	Get a 7-Day Free Trial											366.80	369.03	371.85	373.68	374.76

Vaxxinity Additional Paid-In Capital Calculation

Capital that a company raises in a financing round in excess of the capital's par value. The account represents the excess paid by an investor over the par-value price of a stock issue. Additional paid-in-capital can arise from issuing either preferred or common stock.

Additional Paid-In Capital is calculated as

Additional Paid-In Capital

(Issue Price

Par Value)

Shares Outstanding (Diluted Average)

Vaxxinity Additional Paid-In Capital Related Terms

Thank you for viewing the detailed overview of Vaxxinity's Additional Paid-In Capital provided by GuruFocus.com. Please click on the following links to see related term pages.

Vaxxinity (Vaxxinity) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Vaxxinity Inc (OTCPK:VAXX) » Definitions » Additional Paid-In Capital

Comparable Companies

Traded in Other Exchanges

N/A

Address

505 Odyssey Way, Merritt Island, FL, USA, 32953

Website

https://www.vaxxinity.com

Vaxxinity Inc is engaged in the development and commercialization of prophylactic and therapeutic vaccines to combat chronic disorders and infectious diseases with large patient populations and unmet medical needs. Its pipeline primarily consists of five programs focused on chronic disease, particularly neurodegenerative disorders, in addition to other neurology and cardiovascular indications.

Executives

Sumita Ray	officer: Chief Legal Officer, Secretary	C/O PHARMACYCLICS, INC., 995 EAST ARQUES AVENUE, SUNNYVALE CA 94085
Prime Movers Lab Fund I Lp	10 percent owner	P.O. BOX 12829, JACKSON WY 83002
Landon E Ogilvie	director	505 ODYSSEY WAY, EXPLORATION PARK FL 32953
Katherine A. Eade	director	C/O HARVARD BIOSCIENCE, INC., 84 OCTOBER HILL ROAD #10, HOLLISTON MA 01746
James Alan Smith	director	505 ODYSSEY WAY, EXPLORATION PARK FL 32953
Gabrielle B Toledano	director	209 REDWOOD SHORES PARKWAY, REDWOOD CITY CA 94065
Lou Reese	director, officer: Executive Chairman	C/O VAXXINITY, INC., 1717 MAIN ST STE. 3388, DALLAS TX 75201
Mei Mei Hu	director, 10 percent owner, officer: See Remarks	C/O VAXXINITY, INC., 1717 MAIN ST STE. 3388, DALLAS TX 75201
United Biomedical Inc	10 percent owner	25 DAVIDS DR, HAUPPAUGE NY 11788
Dakin Sloss	10 percent owner	126 E 56TH ST, 30TH FLOOR, NEW YORK NY 10022
Peter Powchik	director	REGENERON PHARMACEUTICALS, INC., 777 OLD SAW MILL RIVER ROAD, TARRYTOWN NY 10591
Jason Pesile	officer: See Remarks	C/O VAXXINITY, INC., 1717 MAIN ST. STE.3388, DALLAS TX 75201
George R Hornig	director	625 MADISON AVE SUITE 10-B, NEW YORK NY 10017
James Chui	director	C/O VAXXINITY, INC., 1717 MAIN ST STE. 3388, DALLAS TX 75201
Peter Diamandis	director	4640 ADMIRALTY WAY, SUITE 500, MARINA DEL REY CA 90292